NT-502

NT-502 is an investigational encapsulated cell therapy (ECT) developed by Neurotech Pharmaceuticals for the treatment of neovascular (wet) age-related macular degeneration (AMD). The therapy consists of a semi-permeable polymer capsule containing human retinal pigment epithelial cells (NTC-200 cell line) that have been genetically engineered to continuously produce and secrete a soluble vascular endothelial growth factor receptor-1 (sFlt-1), which acts as a potent VEGF antagonist. By providing sustained, long-term delivery of the anti-angiogenic protein directly into the vitreous, NT-502 was designed to suppress pathological angiogenesis and vascular permeability while significantly reducing the treatment burden associated with frequent intravitreal injections of standard anti-VEGF agents. Although NT-502 successfully completed Phase 1 clinical testing, its development was subsequently discontinued in favor of the optimized second-generation candidate, NT-503.

Other names

ECT-sFlt1ECT-sFlt-1ECT-sFlt 1